This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CDNF / Cerebral dopamine neurotrophic factor · IHC design guide
Design Immunohistochemistry for CDNF
Plan CDNF staining in paraffin sections using the reported cytoplasmic and nuclear tissue pattern (HPA tissue IHC). Compare controls and interpret staining cautiously because the tissue evidence has uncertain reliability (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CDNF Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Most tissues: cytoplasmic and nuclear cell staining (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A10069-1) | |
| Caveat | Secreted CDNF may appear away from its site of synthesis (UniProt; HPA tissue IHC) | |
| Regulation | No specific expression regulator documented (UniProt) | |
| Isoform / epitope | 2 isoforms; signal peptide 1–24; epitope coverage unknown (UniProt) |
Section 1
Recommended CDNF IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with four published CDNF chromogenic IHC protocols: two paraffin-section methods and two free-floating or cryostat-section methods (PMC9941578; PMC6580362; PMC7645584; PMC10593617).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A10069-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-CDNF, 2.5 μg/mL (datasheet A10069-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CDNF-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 at 95–98 °C for 20 min for the catalog antibody; adjust retrieval for published antibodies only when following their specific methods (page retrieval rule).
Section 2
What Is the Expected CDNF Staining Pattern?
CDNF is a secreted protein with no transmembrane segment (UniProt Q49AH0). In paraffin-section IHC, HPA reports cytoplasmic and nuclear staining in most tissues, including high staining in hepatocytes, pancreatic exocrine glandular cells and skeletal-muscle myocytes (HPA: tissue IHC). Treat this as a provisional pattern: HPA rates the tissue staining Uncertain because antibody staining and RNA expression show low consistency, and secreted protein may appear away from its site of synthesis (HPA: reliability description).
| Cytoplasmic staining, sometimes with nuclear staining, in hepatocytes or pancreatic exocrine glandular cells. | This matches HPA's reported compartments and High staining in these cells (HPA: tissue IHC). Score the cells and compartments separately; HPA rates the pattern Uncertain, so resemblance alone does not establish CDNF specificity (HPA: reliability). |
| Staining appears only as a sharp plasma-membrane rim. | A membrane-only pattern is outside HPA's reported cytoplasmic and nuclear profile (HPA: tissue IHC). CDNF has no transmembrane segment (UniProt Q49AH0 topology). Review morphology and controls before interpreting the rim as target signal (standard IHC practice). |
| Strong staining appears in adipocytes or bone-marrow hematopoietic cells. | HPA reports CDNF as Not detected in these cells (HPA: tissue IHC). Cross-reactivity or detection-system activity is possible; compare a no-primary control and a reported High-staining tissue before assigning specificity (standard IHC practice). |
| Brown color spreads across tissue spaces and lacks clear cell boundaries. | CDNF is secreted, so extracellular signal cannot be ruled out from topology alone (UniProt Q49AH0). Widespread, structure-free color also warrants a background check with a no-primary control; morphology alone cannot resolve its source (standard IHC practice). |
| No staining appears in liver hepatocytes or pancreatic exocrine glandular cells. | Both are reported High by HPA, making them useful comparison tissues (HPA: tissue IHC). Check tissue integrity and the detection run before calling the sample negative (standard IHC practice). HPA's Uncertain rating limits their use as definitive positive controls (HPA: reliability). |
💡Expected CDNF appearanceA plausible positive is discernible cytoplasmic staining, possibly nuclear, in HPA-reported High cells such as hepatocytes; membrane-only rims or structure-free color need control review (HPA: tissue IHC; UniProt Q49AH0 topology; standard IHC practice).
| Secretion and processing | CDNF has a signal peptide at residues 1–24, a mature chain at 25–187 and no transmembrane segment (UniProt Q49AH0). These features make a fixed membrane-rim expectation inappropriate; they do not predict how strongly extracellular material will stain in a section (UniProt Q49AH0 topology). |
| Tissue evidence and RNA | HPA reports High IHC staining in several cell types but rates its tissue profile Uncertain because staining and RNA expression have low consistency (HPA: tissue IHC; HPA: reliability). Its tissue-enhanced RNA calls for skeletal muscle and tongue do not set an IHC intensity threshold (HPA: RNA specificity). |
| Antibody validation | The listed HPA antibody, HPA044587, has an Uncertain IHC assessment (HPA: antibody validation). A matching pattern therefore needs control-based assessment; it is not independently confirmed by this antibody listing (HPA: antibody validation; standard IHC practice). |
| What can IF/ICC confirm here? | HPA lists CDNF as Secreted but provides no main subcellular location or ICC-IF image-bearing cell lines, and no ICC validation status for the listed antibody (HPA: subcellular; HPA: antibody validation). This record cannot establish an expected IF/ICC compartment pattern. |
| Antigen retrieval and fixation | No CDNF-specific retrieval condition or fixation-sensitivity result is supplied by UniProt or HPA (UniProt Q49AH0; HPA: tissue IHC). If signal is weak, assess the validated IHC workflow and controls; do not infer a CDNF fixation effect from tissue staining levels (standard IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| Reported High tissue is blank. | The run may have failed, or the particular section may lack interpretable tissue; a High HPA call is provisional (HPA: tissue IHC; HPA: reliability; standard IHC practice). | Inspect morphology and counterstain, then check the IHC-validated antibody and detection controls before scoring the section negative (standard IHC practice). |
| Low or absent signal throughout the slide. | A preparation, primary-antibody or detection step may have failed (standard IHC practice). HPA's Uncertain assessment prevents treating one blank tissue as proof of true absence (HPA: reliability). | Verify the antibody, retrieval and detection steps against the validated IHC workflow; include a reported High tissue for comparison (standard IHC practice; HPA: tissue IHC). |
| Reported Not detected cells stain strongly. | Possible nonspecific binding or endogenous detection activity, especially if a no-primary control also develops color (standard IHC practice; HPA: tissue IHC). | Run a no-primary control, check blocking and detection chemistry, and compare staining with a reported High cell type (standard IHC practice; HPA: tissue IHC). |
| Uniform haze obscures cell boundaries. | Background from staining or detection can obscure the reported cytoplasmic and nuclear profile (standard IHC practice; HPA: tissue IHC). | Compare with a no-primary control and review washing, blocking and chromogen development in the validated workflow (standard IHC practice). |
| Only membrane rims are visible. | A rim-only pattern does not match HPA's cytoplasmic and nuclear description or CDNF's lack of a transmembrane segment (HPA: tissue IHC; UniProt Q49AH0 topology). | Review section morphology and control slides; withhold a CDNF-positive call until the signal is supported by controls (standard IHC practice). |
| Nuclear staining dominates the result. | HPA does report nuclear staining, but its overall tissue profile is Uncertain; nuclear intensity alone cannot verify specificity (HPA: tissue IHC; HPA: reliability). | Record nuclear and cytoplasmic staining separately, compare reported High and Not detected cells, and inspect the no-primary control (HPA: tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing CDNF staining
A10069-1 · IHCImmunohistochemistry of CDNF in human brain tissue with CDNF antibody at 2.5 μg/mL.
A10069-1 · IHCImmunohistochemistry of CDNF in mouse brain tissue with CDNF Antibody at 5 μg/mL.
A10069-1 · IFImmunofluorescence of CDNF in Human Brain cells with CDNF antibody at 20 μg/mL.
A10069 · IHCImmunohistochemical analysis of paraffin-embedded human-liver, antibody was diluted at 1:200
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/cerebral+cortex#imid_11922231
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/colon#imid_11922165
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/liver#imid_11922158
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/kidney#imid_11922159
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CDNF IHC & IF
🧪Run liver first and assess staining in hepatocytes (HPA: High in hepatocytes). Use oral mucosa squamous epithelial cells as the negative tissue (HPA: Not detected in squamous epithelial cells); on the liver slide, internal negative cells should show only background signal, but no specific liver cell type is established as negative by the supplied HPA row.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for CDNF; derive a cell-line control from the positive tissue's cell type (Glandular cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary (secondary-only) control, plus host-species-matched control IgG for a polyclonal primary or an isotype-matched control for a monoclonal primary (standard IHC practice). Use CDNF knockout tissue, if available, or a cognate peptide-block control to assess specificity; in liver, check endogenous peroxidase and, if using avidin–biotin detection, endogenous biotin (standard IHC practice).
⚠️Feasibility: A CDNF-specific fixation window and antigen-retrieval requirement are unreported in the supplied evidence; the A10069-1 human-brain IHC caption reports 2.5 μg/mL but does not report a fixative (selected-SKU caption: A10069-1). The evidence does not establish whether frozen sections or IF would be easier, and HPA lists no cell line with ICC-IF images (HPA subcellular record). In liver, endogenous peroxidase or biotin can complicate chromogenic interpretation, depending on the detection system (standard IHC practice).
HPA tissue IHC evidence for CDNF
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data. At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | High | Protein (IHC) | HPA → |
| Liver | Hepatocytes | High | Protein (IHC) | HPA → |
| Nasopharynx | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Soft tissue | Fibroblasts | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CDNF IHC Tips
Troubleshoot CDNF staining in paraffin sections by checking retrieval, controls, cellular distribution and scoring before interpreting chromogenic signal.
What retrieval should I try first when CDNF staining is weak?
Start with citrate buffer at pH 6.0 for heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). Keep section thickness, cooling time and detection conditions consistent while comparing a known positive tissue with a no-primary control (standard IHC practice). If staining remains weak, test a second retrieval condition on adjacent sections as a fallback, recording its buffer, pH and heating time rather than changing several variables together (standard IHC practice). CDNF is a secreted protein with no transmembrane segment, so retrieval performance alone cannot establish whether a cellular or extracellular signal is specific (UniProt Q49AH0 topology and subcellular annotation).
Could fixation explain weak or uneven CDNF staining?
Target-specific fixation sensitivity for CDNF is unknown from the supplied evidence; the human brain tissue-IHC caption reports neither fixative nor fixation time (A10069-1 tissue-IHC caption). Record fixative, time to fixation, duration and tissue processing for every paraffin block before comparing staining across specimens (standard IHC practice). Examine adjacent sections from consistently processed blocks and hold retrieval at citrate pH 6.0, 95–98 °C for 20 min while assessing whether the variation persists (page retrieval setting; standard IHC practice). Do not attribute a weak result to CDNF secretion, lack of annotated glycosylation or HPA tissue patterns without a direct fixation comparison (UniProt Q49AH0; HPA tissue IHC).
How should I assess CDNF staining in cells and extracellular areas?
Score cellular and extracellular staining separately because CDNF is annotated as secreted, with no transmembrane segment (UniProt Q49AH0 topology and subcellular annotation). HPA reports cytoplasmic and nuclear staining in most tissues, but rates its tissue-IHC reliability Uncertain because staining and RNA expression have low consistency (HPA tissue IHC). Compare the distribution with tissue architecture and a no-primary control; diffuse precipitate across tissue edges or empty spaces needs further checking before it is called extracellular CDNF (standard IHC practice). Annotate cell type, compartment and staining intensity on matched sections rather than assigning all brown signal to one CDNF pool (standard IHC practice).
Could the antibody epitope change which CDNF forms I detect?
CDNF has 2 annotated isoforms, a signal peptide at residues 1–24, and a chain at residues 25–187 (UniProt Q49AH0). Check the catalog antibody’s stated immunogen or epitope before interpreting staining, because the supplied caption does not map its binding site (A10069-1 tissue-IHC caption). If that information is unavailable, describe the result as antibody staining rather than assigning it to one isoform or to precursor versus processed CDNF (UniProt Q49AH0; standard IHC interpretation practice). Compare sections with the same retrieval and detection settings, and use an independently validated epitope reagent if isoform or processing specificity is essential (standard IHC practice).
How can I adapt a CDNF tissue finding for multiplex immunofluorescence?
Treat multiplex IF as a separate assay: the supplied A10069-1 evidence is a tissue-IHC caption reporting 2.5 µg/mL in human brain, without IF conditions (A10069-1 tissue-IHC caption). Pair CDNF with a validated marker for the cell population being examined, and compare single-label controls before interpreting colocalisation (standard IF practice). Choose fluorophores and filter channels after checking autofluorescence in an unstained section, favouring a channel with clear separation from that background (standard IF practice). If the mapped epitope is intracellular, assess permeabilisation on matched sections; if it is extracellular, assess staining without permeabilisation first, since CDNF is secreted and the supplied evidence does not locate this antibody’s epitope (UniProt Q49AH0; A10069-1 tissue-IHC caption).
What controls help identify false CDNF chromogenic signal?
Run a no-primary control through the same secondary detection, peroxidase block and DAB development used for the test section (standard chromogenic IHC practice). If brown signal persists, inspect endogenous enzyme activity, nonspecific secondary binding and precipitated chromogen before changing the CDNF antibody concentration (standard IHC practice). The only supplied concentration for A10069-1 is 2.5 µg/mL in a human brain tissue-IHC image; it is a reported staining condition, not a background-free optimum (A10069-1 tissue-IHC caption). Compare matched tissue regions and development times, especially near edges or damaged areas where deposition can imitate cellular or extracellular staining (standard IHC practice).
How should I quantify CDNF staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and eligible cell population before scoring, then use an H-score combining intensity and percentage of positive cells for cellular CDNF staining (standard IHC practice). Report the % positive cells separately, or positive-cell density per mm² when tissue area and cell counts are the relevant denominators (standard IHC practice). Normalise each measure to the same viable tissue area or the same number of eligible cells, and keep retrieval, imaging and DAB development consistent across specimens (standard IHC practice). Record extracellular signal separately because CDNF is secreted, and avoid treating HPA’s Uncertain tissue-IHC profile as a calibration standard (UniProt Q49AH0; HPA tissue IHC).
When should I question an apparent CDNF-positive region?
Question staining confined to tissue edges, necrotic areas or no-primary controls, and check whether endogenous peroxidase or DAB precipitate explains it (standard chromogenic IHC practice). Verify the apparent positive cell type against morphology and matched controls: HPA reports high staining in hepatocytes but no detection in adipocytes, while rating its overall tissue-IHC reliability Uncertain (HPA tissue IHC). A strictly membrane-bound pattern warrants scrutiny because CDNF has no transmembrane segment, although its secreted annotation does not by itself identify every stained compartment (UniProt Q49AH0 topology and subcellular annotation). Treat nuclear or extracellular signal cautiously until it reproduces with appropriate controls, given HPA’s reported cytoplasmic and nuclear profile and its low staining–RNA consistency (HPA tissue IHC; standard IHC practice).
Boster reagents
Best CDNF / Cerebral dopamine neurotrophic factor IHC Antibodies
Anti-CDNF antibodies have IHC images from human brain, mouse brain, and paraffin-embedded human liver (catalog image captions). IF images cover human brain cells and mouse brain tissue (A10069-1 image captions).
Real IHC data
Anti-CDNF Antibody
Cat # A10069-1
Real IHC data
Anti-CDNF Antibody
Cat # A10069
A10069-1 has IHC-P images from human and mouse brain and IF images from human brain cells and mouse brain tissue (A10069-1 applications and image captions). A10069 has an IHC image from paraffin-embedded human liver; IF is listed as an application, but no IF image is supplied (A10069 applications and image captions).
Which to pick: For brain tissue IHC, choose A10069-1 based on its human and mouse brain IHC images; for paraffin-embedded human liver, choose A10069 based on its own IHC caption (catalog image captions). For IF/ICC, A10069-1 has an image from human brain cells, while A10069 lists IF without an image (catalog applications and image captions). Both list human, mouse, and rat reactivity and a rabbit host, but neither provides a clone designation; the captions do not report the fixative (catalog reactivity, host, clone fields, and image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q49AH0 (CDNF_HUMAN, Cerebral dopamine neurotrophic factor).
- Human Protein Atlas. CDNF tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. CDNF subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. CDNF antibody validation summary (1 antibodies).
- Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington's disease. Scientific reports 2023 — PMC9941578.
- Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. Frontiers in neuroscience 2019 — PMC6580362.
- Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease. Scientific reports 2020 — PMC7645584.
- Sex and age differences in mice models of effort-based decision-making and anergia in depression: the role of dopamine, and cerebral-dopamine-neurotrophic-factor. Psychopharmacology 2023 — PMC10593617.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:17611540 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CDNF (Cerebral dopamine neurotrophic factor). Expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10069-1 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A10069-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-CDNF, 2.5 μg/mL (datasheet A10069-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A10069-1); Caveat: Secreted CDNF may appear away from its site of synthesis (UniProt; HPA tissue IHC); Isoform / epitope: 2 isoforms; signal peptide 1–24; epitope coverage unknown (UniProt); Regulation: No specific expression regulator documented (UniProt). Evidence: UniProt Q49AH0, HPA tissue IHC · Uncertain, HPA ICC-IF · Secreted, Datasheet A10069-1, PMC9941578, PMC6580362. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CDNF/immunohistochemistry-ihc-guide.